Reduction by Hange-Shashin-To (TJ-14), a herbal medicine on gastrointestinal tract complications induced by CPT-11 containing chemotherapy

Cancer Research Therapy and Control

Volumn 7, Issue 4, 1999, Pages 321-323

  Satoh, Hiroaki ^a   Ishikawa, Hiroichi ^a   Murakami, Osamu ^a   Yamashita, Yuko T ^a   Maeno, Tetsuhiro ^a   Kamma, Hiroshi ^a   Ohtsuka, Morio ^a   Hasegawa, Shizuo ^a  

^a UNIVERSITY OF TSUKUBA   (Japan)

Author keywords

Chemotherapy; CPT 11; Hange Shashin To; Herbal medicine

Indexed keywords

BAICALIN; CAMPTOTHECIN; CISPLATIN; HANGE SHASHIN TO; IRINOTECAN; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CHEMOPROPHYLAXIS; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; FEMALE; GASTROINTESTINAL SYMPTOM; HERBAL MEDICINE; HUMAN; LUNG CANCER; MALE; ODOR; PARALYTIC ILEUS; PRIORITY JOURNAL; TASTE;

EID: 0032971355     PISSN: 10640525     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Abigerges D, Armand JP, Chabot GG, et al. (1994). Irinotecan (CPT-11) high-dose escalation using intensive high-dose loperamide to control diarrhea. J Natl Cancer Inst, 86,446-449.
2. Araki E, Ishikawa M, ligo M, et al. (1993). Relationship between development of diarrhea and the concentration of SN-38, an active metabolite of CPT-11, in the intestine and the blood plasma of athymic mice following intraperitoneal administration of CPT11. Jpn J Cancer Res, 84, 697-702.
3. Atsumi R, Suzuki W, Hakusui H. (1991). Identification of the metabolites of irinotecan, a new derivative of camptothecin, in rat bile and its biliary excretion. Xenobiotica, 21, 1159-1169.
4. Fukuoka M, Niitani H, SuzukiA, et al. (1992). A phase II study of CPT-11, a new derivative of camptothecin, for previously untreated non-small-cell lung cancer. J Clin Oncol, 10, 16-20.
5. Kaneda N, Yokokura T. (1990). Nonlinear pharmacokinetics of CPT-11 in rats. Cancer Res, 50, 1721-1725.
6. Kunimoto T, Nitta K, Tanaka T, et al. (1987). Antitumor activity of 7-ethyl-10 -[4- (1 -piperidino)-l-piperidino]carbonyloxycamptothecin, against murine tumors. Cancer Res, 47, 59445947.
7. Narita M, Nagai E, Hagiwara H, et al. (1993). Inhibition of beta-glucuronidase by natural glucuronides of Kampo medicines using glucuronide of SN-38 (7-ethyl-10-hydroxycamtothecin) as a substrate. Xenobiotica, 23, 5-10.
8. Negoro S, Fukuoka M, Masuda N, et al. (1991). Phase I study of weekly intravenous infusion of CPT-11, a new derivative of camptothecin, in the treatment of advanced non-small-cell lung cancer. J Natl Cancer Inst, 83, 1164-1168.
9. Ohé Y, Sasaki Y, Shinkai T, et al. (1990). Phase I study and pharmacokinetics of CPT-11 with 5-day continuous infusion. J Natl Cancer Inst 84, 972-974.
10. Ohno R, Okada K, Masaoka T, et al. (1990). An early phase II study of CPT-11 : a new derivative of camptothecin, for the treatment of leukemia and lymphoma. J Clin Oncol, 8, 19071912.
11. Sakata Y, Suzuki H, Kamataki T. (1994). Preventive effect of TJ-14, a Kampo (Chinese herb) medicine, on diarrhea induced by irinotecan hydrochloride (CPT-11). Jpn J Cancer Chemother, 21, 1241-1244.
12. Shimada Y, Yoshino M, Wakui A, et al. (1993). Phase II study of CPT-11, a new camptothecin derivative, in metastatic colorectal cancer. J Clin Oncol, 11, 909-913.
13. Taguchi T, Wakui A, Hasegawa K, et al. (1990). Phase I clinical study of CFT-11. Jpn J Cancer Chemother, 17, 115-120.
14. Takasuna K, Kasai Y, Kitano Y, et al. (1995). Protective effect of Kampo medicines and baicalin against intestinal toxicity of a new anticancer camptothecin derivative, irinotecan hydrochloride (CPT-11), in rats. Jpn J Cancer Res, 86, 978-984.